Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Apr 8;4(4):CD004679.
doi: 10.1002/14651858.CD004679.pub3.

Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients

Denise Campbell  1 , David W Mudge  2 , Jonathan C Craig  3   4 , David W Johnson  5 , Allison Tong  1   3 , Giovanni Fm Strippoli  3   4   6   7   8
Affiliations
Review

Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients

Denise Campbell et al. Cochrane Database Syst Rev. .

Abstract

Background: Peritoneal dialysis (PD) is an important therapy for patients with end-stage kidney disease and is used in more than 200,000 such patients globally. However, its value is often limited by the development of infections such as peritonitis and exit-site and tunnel infections. Multiple strategies have been developed to reduce the risk of peritonitis including antibiotics, topical disinfectants to the exit site and antifungal agents. However, the effectiveness of these strategies has been variable and are based on a small number of randomised controlled trials (RCTs). The optimal preventive strategies to reduce the occurrence of peritonitis remain unclear.This is an update of a Cochrane review first published in 2004.

Objectives: To evaluate the benefits and harms of antimicrobial strategies used to prevent peritonitis in PD patients.

Search methods: We searched the Cochrane Kidney and Transplant's Specialised Register to 4 October 2016 through contact with the Information Specialist using search terms relevant to this review. Studies contained in the Specialised Register are identified through search strategies specifically designed for CENTRAL, MEDLINE, and EMBASE; handsearching conference proceedings; and searching the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.

Selection criteria: RCTs or quasi-RCTs in patients receiving chronic PD, which evaluated any antimicrobial agents used systemically or locally to prevent peritonitis or exit-site/tunnel infection were included.

Data collection and analysis: Two authors independently assessed risk of bias and extracted data. Summary estimates of effect were obtained using a random-effects model, and results were expressed as risk ratio (RR) with 95% confidence intervals (CI).

Main results: Thirty-nine studies, randomising 4435 patients, were included. Twenty additional studies have been included in this update. The risk of bias domains were often unclear or high; risk of bias was judged to be low in 19 (49%) studies for random sequence generation, 12 (31%) studies for allocation concealment, 22 (56%) studies for incomplete outcome reporting, and in 12 (31%) studies for selective outcome reporting. Blinding of participants and personnel was considered to be at low risk of bias in 8 (21%) and 10 studies (26%) for blinding of outcome assessors. It should be noted that blinding of participants and personnel was not possible in many of the studies because of the nature of the intervention or control treatment.The use of oral or topical antibiotic compared with placebo/no treatment, had uncertain effects on the risk of exit-site/tunnel infection (3 studies, 191 patients, low quality evidence: RR 0.45, 95% CI 0.19 to 1.04) and the risk of peritonitis (5 studies, 395 patients, low quality evidence: RR 0.82, 95% CI 0.57 to 1.19).The use of nasal antibiotic compared with placebo/no treatment had uncertain effects on the risk of exit-site/tunnel infection (3 studies, 338 patients, low quality evidence: RR 1.34, 95% CI 0.62 to 2.87) and the risk of peritonitis (3 studies, 338 patients, low quality evidence: RR 0.94, 95% CI 0.67 to 1.31).Pre/perioperative intravenous vancomycin compared with no treatment may reduce the risk of early peritonitis (1 study, 177 patients, low quality evidence: RR 0.08, 95% CI 0.01 to 0.61) but has an uncertain effect on the risk of exit-site/tunnel infection (1 study, 177 patients, low quality evidence: RR 0.36, 95% CI 0.10 to 1.32).The use of topical disinfectant compared with standard care or other active treatment (antibiotic or other disinfectant) had uncertain effects on the risk of exit-site/tunnel infection (8 studies, 973 patients, low quality evidence, RR 1.00, 95% CI 0.75 to 1.33) and the risk of peritonitis (6 studies, 853 patients, low quality evidence: RR 0.83, 95% CI 0.65 to 1.06).Antifungal prophylaxis with oral nystatin/fluconazole compared with placebo/no treatment may reduce the risk of fungal peritonitis occurring after a patient has had an antibiotic course (2 studies, 817 patients, low quality evidence: RR 0.28, 95% CI 0.12 to 0.63).No intervention reduced the risk of catheter removal or replacement. Most of the available studies were small and of suboptimal quality. Only six studies enrolled 200 or more patients.

Authors' conclusions: In this update, we identified limited data from RCTs and quasi-RCTs which evaluated strategies to prevent peritonitis and exit-site/tunnel infections. This review demonstrates that pre/peri-operative intravenous vancomycin may reduce the risk of early peritonitis and that antifungal prophylaxis with oral nystatin or fluconazole reduces the risk of fungal peritonitis following an antibiotic course. However, no other antimicrobial interventions have proven efficacy. In particular, the use of nasal antibiotic to eradicate Staphylococcus aureus, had an uncertain effect on the risk of peritonitis and raises questions about the usefulness of this approach. Given the large number of patients on PD and the importance of peritonitis, the lack of adequately powered and high quality RCTs to inform decision making about strategies to prevent peritonitis is striking.

PubMed Disclaimer

Conflict of interest statement

  1. Denise Campbell: none

  2. David W Mudge has received consultancy fees, speakers' honoraria and travel assistance from Baxter Healthcare for activities unrelated to this review

  3. Jonathan C Craig: none

  4. David W Johnson has received consultancy fees, speakers' honoraria, travel sponsorships and research funding from Fresenius Medical Care and Baxter Healthcare for activities unrelated to this review

  5. Allison Tong: none

  6. Giovanni FM Strippoli: none

Figures

1
1
Study flow diagram.
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Axelrod 1973 {published data only}
    1. Axelrod J, Meyers BR, Hirschman SZ, Stein R. Prophylaxis with cephalothin in peritoneal dialysis. Archives of Internal Medicine 1973;132(3):368‐71. [MEDLINE: ] - PubMed
Bennet‐Jones 1988 {published data only}
    1. Bennet‐Jones D, Martin J, Barratt AJ, Duffy TJ, Naish PF, Aber GM. Prophylactic gentamicin in the prevention of early exit‐site infections and peritonitis in CAPD. Advances in Peritoneal Dialysis 1988;4:147‐50. [CENTRAL: CN‐00775909]
Bernardini 1996 {published data only}
    1. Bernardini J, Piraino B, Holley J, Johnston JR, Lutes R. A randomized trial of staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin. American Journal of Kidney Diseases 1996;27(5):695‐700. [MEDLINE: ] - PubMed
Bernardini 2005 {published data only}
    1. Bernardini J, Bender F, Florio T, Sloand J, Palmmontalbano L, Fried L, et al. Randomized, double‐blind trial of antibiotic exit site cream for prevention of exit site infection in peritoneal dialysis patients. Journal of the American Society of Nephrology 2005;16(2):539‐45. [MEDLINE: ] - PubMed
Blowey 1994 {published data only}
    1. Blowey DL, Warady BA, McFarland KS. Treatment of staphylococcus aureus nasal carriage in pediatric peritoneal dialysis patients. Advances in Peritoneal Dialysis 1994;10:297‐9. [MEDLINE: ] - PubMed
Cheng 1999a {published data only}
    1. Cheng YY, Ho YW, Chiu SW. Exit site care, an open labelled randomized prospective study comparing the use of povidone‐iodine and chlorhexidine soap [abstract no: 6]. Hong Kong Journal of Nephrology 1999;1(1):A3.
Chu 2008 {published data only}
    1. Chu KH, Choy WY, Cheung CC, Fung KS, Tang HL, Lee W, et al. A prospective study of the efficacy of local application of gentamicin versus mupirocin in the prevention of peritoneal dialysis catheter‐related infections. Peritoneal Dialysis International 2008;28(5):505‐8. [MEDLINE: ] - PubMed
Churchill 1988 {published data only}
    1. Churchill DN, Oreopoulos DG, Taylor DW, Vas SI, Manuel MA, Wu G. Peritonitis in CAPD patients ‐ a randomized clinical trial (RCT) of trimethoprim‐sulfamethoxazole (TMP/SMX) prophylaxis [abstract]. Kidney International 1988;33(1):244. [CENTRAL: CN‐00636126]
    1. Churchill DN, Taylor DW, Vas SI, Singer J, Beecroft ML, Wu G, et al. Peritonitis in continuous ambulatory peritoneal dialysis (CAPD) patients: a randomized clinical trial of cotrimoxazole prophylaxis. Peritoneal Dialysis International 1988;8(2):125‐8. [EMBASE: 18252568]
Cocksedge 1993 {published data only}
    1. Cocksedge B, Hunt D, Westerholm W, Heathcote K, Pollock C. Peritoneal dialysis catheter exit site care for the maintenance continuous ambulatory peritoneal dialysis (CAPD) patient: report of a randomised prospective study. Renal Educator 1993;13(1):4‐6. [CENTRAL: CN‐00626103]
Danguilan 2003 {published data only}
    1. Danguilan RA, Evangelista LP, Abrenica MS, Rondilla SM. Comparative study of mupirocin and sodium fucidate in the prophylaxis of exit‐site infections in CAPD patients. Peritoneal Dialysis International 2003;23(6):593‐5. [MEDLINE: ] - PubMed
Fuchs 1990 {published data only}
    1. Fuchs J, Gallagher ME, Jackson‐Bey D, Krawtz D, Schreiber J. A prospective randomized study of peritoneal catheter exit‐site care. Dialysis & Transplantation 1990;19(2):81‐4. [EMBASE: 20066020]
Gadallah 2000c {published data only}
    1. Gadallah MF, Ramdeen G, Mignone J, Patel D, Mitchell L, Tatro S. Role of preoperative antibiotic prophylaxis in preventing postoperative peritonitis in newly placed peritoneal dialysis catheters. American Journal of Kidney Diseases 2000;36(5):1014‐9. [MEDLINE: ] - PubMed
    1. Gadallah MF, Ramdeen G, Torres C, Mignone J, Patel D, Mitchell L, et al. Preoperative vancomycin prophylaxis for newly placed peritoneal dialysis catheters prevents postoperative peritonitis. Advances in Peritoneal Dialysis 2000;16:199‐203. [MEDLINE: ] - PubMed
HONEYPOT Study 2009 {published data only}
    1. Johnson DW, Badve SV, Pascoe EM, Beller E, Cass A, Clark C, et al. Antibacterial honey for the prevention of peritoneal‐dialysis‐related infections (HONEYPOT): a randomised trial. Lancet Infectious Diseases 2014;14(1):23‐30. [MEDLINE: ] - PubMed
    1. Johnson DW, Clark C, Isbel NM, Hawley CM, Beller E, Cass A, et al. The Honeypot study protocol: a randomized controlled trial of exit‐site application of medihoney antibacterial wound gel for the prevention of catheter‐associated infections in peritoneal dialysis patients. Peritoneal Dialysis International 2009;29(3):303‐9. [MEDLINE: ] - PubMed
    1. Pascoe EM, Lo S, Scaria A, Badve SV, Beller EM, Cass A, et al. The HONEYPOT randomized controlled trial statistical analysis plan. Peritoneal Dialysis International 2013;33(4):426‐35. [MEDLINE: ] - PMC - PubMed
    1. Zhang L, Badve SV, Pascoe EM, Beller E, Cass A, Clark C, et al. Microbiological results of the Honeypot study‐secondary analysis of a randomised, controlled trial of exit site application of MEDIHONEY for the prevention of catheter‐associated infections in PD patients [abstract]. Nephrology 2014;19(Suppl 4):30. [EMBASE: 71587829]
    1. Zhang L, Badve SV, Pascoe EM, Beller E, Cass A, Clark C, et al. The effect of exit‐site antibacterial honey versus nasal mupirocin prophylaxis on the microbiology and outcomes of peritoneal dialysis‐associated peritonitis and exit‐site infections: a sub‐study of the Honeypot Trial. Peritoneal Dialysis International 2015;35(7):712‐21. [MEDLINE: ] - PMC - PubMed
Lo 1996 {published data only}
    1. Lo WK, Chan CY, Cheng SW, Poon JF, Chan DT, Cheng IK. A prospective randomized control study of oral nystatin prophylaxis for Candida peritonitis complicating continuous ambulatory peritoneal dialysis. American Journal of Kidney Diseases 1996;28(4):549‐52. [MEDLINE: ] - PubMed
Low 1980 {published data only}
    1. Low DE, Vas S, Oreopoulos DG, Manuel A, Saiphoo C, Finer C, et al. Randomized clinical trial of cephalexin in preventing peritonitis in patients on continuous ambulatory peritoneal dialysis [abstract]. Kidney International 1981;19(2):392.
    1. Low DE, Vas SI, Oreopoulos DG, Manuel MA, Saiphoo MM, Finer C, et al. Prophylactic cephalexin ineffective in chronic ambulatory peritoneal dialysis. Lancet 1980;2(8197):753‐4. [MEDLINE: ] - PubMed
Luzar 1990 {published data only}
    1. Luzar MA, Brown CB, Balf D, Hill L, Issad B, Monnier B, et al. Exit‐site care and exit‐site infection in continuous ambulatory peritoneal dialysis (CAPD): results of a randomized multicenter trial. Peritoneal Dialysis International 1990;10(1):25‐9. [MEDLINE: ] - PubMed
Lye 1992 {published data only}
    1. Lye WC, Lee EJ, Tan CC. Prophylactic antibiotics in the insertion of Tenckhoff catheters. Scandinavian Journal of Urology & Nephrology 1992;26(2):177‐80. [MEDLINE: ] - PubMed
    1. Lye WC, Straaten JC, Lee EJ. A prospective study on the use of prophylactic antibiotics for the implantation of tenckhoff catheters in CAPD patients [abstract]. 12th International Congress of Nephrology; 1993 Jun 13‐18; Jerusalem, Israel. 1993:343. [CENTRAL: CN‐00626018]
Mendoza‐Guevara 2007 {published data only}
    1. Mendoza‐Guevara L, Castro‐Vazquez F, Aguilar‐Kitsu A, Morales‐Nava A, Rodriguez‐Leyva F, Sanchez‐Barbosa JL. Amuchina 10% solution, safe antiseptic for preventing infections of exit‐site of Tenckhoff catheters, in the pediatric population of a dialysis program. Contributions to Nephrology 2007;154:139‐44. [MEDLINE: ] - PubMed
Moore 1989 {published data only}
    1. Moore C. A clinical study comparing a polyurethane dressing, blisterfilm, to standard gauze dressing on the tenckhoff catheter [abstract]. ANNA Journal 1989;16(2):105.
    1. Moore CG. Comparison of Blisterfilm and gauze for peritoneal catheter exit site care. ANNA Journal 1989;16(7):475‐8. [MEDLINE: ] - PubMed
MP3 Study 2008 {published data only}
    1. Jassal SV, Lok CE, MP3 Study Group. A randomized controlled trial comparing mupirocin versus polysporin triple for the prevention of catheter‐related infections in peritoneal dialysis patients (the MP3 study). Peritoneal Dialysis International 2008;28(1):67‐72. [MEDLINE: ] - PubMed
    1. McQuillan RF, Chiu E, Nessim S, Lok CE, Roscoe JM, Tam P, et al. A randomized controlled trial comparing mupirocin and polysporin triple ointments in peritoneal dialysis patients: the MP3 Study. Clinical Journal of the American Society of Nephrology: CJASN 2012;7(2):297‐303. [MEDLINE: ] - PMC - PubMed
    1. Diepen AT, Tomlinson GA, Jassal SV. The association between exit site infection and subsequent peritonitis among peritoneal dialysis patients. Clinical Journal of the American Society of Nephrology: CJASN 2012;7(8):1266‐71. [MEDLINE: ] - PMC - PubMed
Mupirocin Study 1996 {published data only}
    1. Anonymous. Nasal mupirocin prevents staphylococcus aureus exit‐site infection during peritoneal dialysis. Mupirocin Study Group. Journal of the American Society of Nephrology 1996;7(11):2403‐8. [MEDLINE: ] - PubMed
    1. Coles GA, Mupirocin Study Group. The effect of intranasal mupirocin on CAPD exit site infection (ESI) [abstract]. Journal of the American Society of Nephrology 1994;5(3):439. [CENTRAL: CN‐00550592]
    1. Davey P, Craig AM, Hau C, Malek M. Cost‐effectiveness of prophylactic nasal mupirocin in patients undergoing peritoneal dialysis based on a randomized placebo‐controlled trial. Journal of Antimicrobial Chemotherapy 1999;43(1):105‐12. [MEDLINE: ] - PubMed
Nolph 1985 {published data only}
    1. Nolph KD, Prowant B, Serkes KD, Morgan LM. A randomized multicenter clinical trial to evaluate the effects of an ultraviolet germicidal system on peritonitis rate in continuous ambulatory peritoneal dialysis. Peritoneal Dialysis Bulletin 1985;5(1):19‐24. [EMBASE: 15143789]
Nunez‐Moral 2014 {published data only}
    1. Nunez‐Moral M, Sanchez‐Alvarez E, Gonzalez‐Diaz I, Pelaez‐Requejo B, Fernandez‐Vina A, Quintana‐Fernandez A, et al. Exit‐site infection of peritoneal catheter is reduced by the use of polyhexanide. results of a prospective randomized trial. Peritoneal Dialysis International 2014;34(3):271‐7. [MEDLINE: ] - PMC - PubMed
Perez‐Fontan 1992 {published data only}
    1. Perez‐Fontan M, Rosales M, Rodriguez‐Carmona A, Moncalian J, Femindez‐Rivera C, Cao M, et al. Treatment of staphylococcus aureus nasal carriers in CAPD with mupirocin. Advances in Peritoneal Dialysis 1992;8:242‐5. [MEDLINE: ] - PubMed
Poole‐Warren 1991 {published data only}
    1. Poole‐Warren LA, Hallett MD, Hone PW, Burden SH, Farrell PC. Vaccination for prevention of CAPD associated staphylococcal infection: results of a prospective multicentre clinical trial. Clinical Nephrology 1991;35(5):198‐206. [MEDLINE: ] - PubMed
Restrepo 2010 {published data only}
    1. Restrepo C, Chacon J, Manjarres G. Fungal peritonitis in peritoneal dialysis patients: successful prophylaxis with fluconazole, as demonstrated by prospective randomized control trial.[Erratum appears in Perit Dial Int. 2011 Mar‐Apr;31(2):120]. Peritoneal Dialysis International 2010;30(6):619‐25. [MEDLINE: ] - PubMed
Ryckelynck 1987 {published data only}
    1. Ryckelynck JP, Verger C, Cam G, Faller B, Pierre D. A prospective study to evaluate the role of antiseptics in CAPD Y‐line systems [abstract]. 24th Annual Congress. EDTA‐ERA; 1987 Oct 25‐29; West Berlin, Germany. 1987:161. [CENTRAL: CN‐00644147]
Sesso 1994 {published data only}
    1. Sesso R, Parisio K, Dalboni A, Rabelo T, Barbosa D, Cendoroglo M, et al. Effect of sodium fusidate and ofloxacin on staphylococcus aureus colonization and infection in patients on continuous ambulatory peritoneal dialysis. Clinical Nephrology 1994;41(6):370‐6. [MEDLINE: ] - PubMed
    1. Sesso R, Parisio K, Draibe S, Ajzen H. Effect of sodium fusidate and ofloxacin on staphylococcus aureus carriage and infection in patients on peritoneal dialysis (CAPD) [abstract]. Journal of the American Society of Nephrology 1993;4(Program & Abstracts):417. [CENTRAL: CN‐00485819] - PubMed
Sharma 1971 {published data only}
    1. Sharma BK, Rodriguez H, Ghandi VC, Smith EC, Pillay VK, Dunea G. Trial of oral neomycin during peritoneal dialysis. American Journal of the Medical Sciences 1971;262(3):175‐8. [MEDLINE: ] - PubMed
SIPROCE Study 1997 {published data only}
    1. Pommer W. The efficiency of a silver ring to prevent exit‐site and other catheter‐related infections in PD‐patients‐final results of the SIPROCE study [abstract]. Journal of the American Society of Nephrology 1997;8:182A. [CENTRAL: CN‐00447255]
    1. Pommer W, Brauner M, Westphale HJ, Brunkhorst R, Kramer R, Bundschu D, et al. Effect of a silver device in preventing catheter‐related infections in peritoneal dialysis patients: silver ring prophylaxis at the catheter exit study. American Journal of Kidney Diseases 1998;32(5):752‐60. [MEDLINE: ] - PubMed
    1. SIPROCE Study. Efficiency of a silver ring in preventing exit‐site infections in adult PD patients: results of the SIPROCE Study. Silver ring Prophylaxis of the Catheter Exit Site. Advances in Peritoneal Dialysis 1997;13:227‐32. [MEDLINE: ] - PubMed
Sit 2007 {published data only}
    1. Sit D, Kadiroglu AK, Kayabasi H, Yilmaz ME. Prophylactic intranasal mupirocin ointment in the treatment of peritonitis in continuous ambulatory peritoneal dialysis patients. Advances in Therapy 2007;24(2):387‐93. [MEDLINE: ] - PubMed
Swartz 1991 {published data only}
    1. Swartz R, Messana J, Starmann B, Weber M, Reynolds J. Preventing Staphylococcus aureus infection during chronic peritoneal dialysis. Journal of the American Society of Nephrology 1991;2(6):1085‐91. [MEDLINE: ] - PubMed
Wadhwa 1995 {published data only}
    1. Wadhwa NK, Suh H, Cabralda T, Stratos J, Cascio C, Irwin C, et al. A randomized trial of amuchina 10% versus povidone‐iodine 10% solution for exit‐site care/infection in peritoneal dialysis patients [abstract]. Peritoneal Dialysis International 1995;15(Suppl 1):S64.
Wadhwa 1997 {published data only}
    1. Wadhwa NK, Suh H, Cabralda T. Amuchina 5% versus povidone‐iodine 10% solution for exit‐site care/infection in peritoneal dialysis patients [abstract]. Peritoneal Dialysis International 1997;17(Suppl 1):S46.
Waite 1997 {published data only}
    1. Waite N, Webster N, Laurel M, Johnson M, Fong IW. The efficacy of exit site povidone‐iodine ointment in the prevention of early peritoneal dialysis‐related infections. American Journal of Kidney Diseases 1997;29(5):763‐8. [MEDLINE: ] - PubMed
Wikdahl 1997 {published data only}
    1. Wikdahl AM, Engman U, Stegmayr BJ, Sorenson JG. One‐dose cefuroxime i.v. and i.p. reduces microbial growth in PD patients after catheter insertion. Nephrology Dialysis Transplantation 1997;12(1):157‐60. [MEDLINE: ] - PubMed
Wilson 1997 {published data only}
    1. Wilson AP, Lewis C, O'Sullivan HO, Shetty N, Neild GH, Mansell M. The use of povidone iodine in exit site care for patients undergoing continuous peritoneal dialysis (CAPD). Journal of Hospital Infection 1997;35(4):287‐93. [MEDLINE: ] - PubMed
Wong 2003 {published data only}
    1. Wong SS, Chu KH, Cheuk A, Tsang WK, Fung SK, Chan HW, et al. Prophylaxis against gram‐positive organisms causing exit‐site infection and peritonitis in continuous ambulatory peritoneal dialysis patients by applying mupirocin ointment at the catheter exit site. Peritoneal Dialysis International 2003;23 Suppl 2:S153‐8. [MEDLINE: ] - PubMed
Zimmerman 1991 {published data only}
    1. Zimmerman SW, Ahrens E, Johnson CA, Craig W, Leggett J, O'Brien M, et al. Randomized controlled trial of prophylactic rifampin for peritoneal dialysis‐related infections. American Journal of Kidney Diseases 1991;18(2):225‐31. [MEDLINE: ] - PubMed
    1. Zimmerman SW, Ahrens E, Johnson CA, Craig W, Leggett J, O'Brien M, et al. Randomized, controlled trial of prophylactic rifampin (RIF) for PD catheter‐related infections (CRI) and peritonitis (P) [abstract]. Kidney International 1990;37(1):335.

References to studies excluded from this review

Cavdar 2004 {published data only}
    1. Cavdar C, Saglam F, Sifil A, Celik A, Atay T, Gungor O, et al. Effect of once‐a‐week vs thrice‐a‐week application of mupirocin on methicillin and mupirocin resistance in peritoneal dialysis patients: three years of experience. Renal Failure 2008;30(4):417‐22. [MEDLINE: ] - PubMed
    1. Cavdar C, Zeybel M, Atay T, Sifil A, Sanlidag C, Gulay Z, et al. The effects of once‐ or thrice‐weekly mupirocin application on mupirocin resistance in patients on continuous ambulatory peritoneal dialysis‐‐first 6 months' experience. Advances in Peritoneal Dialysis 2004;20:62‐6. [MEDLINE: ] - PubMed
Churchill 1989 {published data only}
    1. Churchill DN, Canadian CAPD Clinical Trials Group. Randomized clinical trial (RCT) comparing peritonitis rates among new CAPD patients using the Y set disinfectant system (Y) to standard systems (S) [abstract]. Kidney International 1989;35(1):268. [CENTRAL: CN‐00602155]
    1. Churchill DN, Taylor DW, Vas SI, Oreopoulos DG, Bettcher KB, Fenton SA, et al. Peritonitis in continuous ambulatory peritoneal dialysis (CAPD): a multi‐centre randomized clinical trial comparing the Y connector disinfectant system to standard systems. Peritoneal Dialysis International 1989;9(3):159‐63. [MEDLINE: ] - PubMed
Crabtree 2003 {published data only}
    1. Crabtree JH, Burchette RJ, Siddiqi RA, Huen IT, Hadnott LL, Fishman A. The efficacy of silver‐ion implanted catheters in reducing peritoneal dialysis‐related infections. Peritoneal Dialysis International 2003;23(4):368‐74. [MEDLINE: ] - PubMed
de Fijter 1992a {published data only}
    1. Fijter CW, Biemond A, Oe LP, Moesker HL, Verhoef J, Donker AJ, et al. Pharmacokinetics of ciprofloxacin after intraperitoneal administration in uninfected patients undergoing CCPD. Advances in Peritoneal Dialysis 1992;8:18‐21. [MEDLINE: ] - PubMed
Gadallah 2000 {published data only}
    1. Gadallah MF, Tamayo A, Sandborn M, Ramdeen G, Moles K. Role of intraperitoneal urokinase in acute peritonitis and prevention of catheter loss in peritoneal dialysis patients. Advances in Peritoneal Dialysis 2000;16:233‐6. [MEDLINE: ] - PubMed
Maiorca 1983 {published data only}
    1. Maiorca R, Cantaluppi A, Cancarini GC, Scalamogna A, Broccoli R, Graziani G, et al. Prospective controlled trial of a Y‐connector and disinfectant to prevent peritonitis in continuous ambulatory peritoneal dialysis. Lancet 1983;2(8351):642‐4. [MEDLINE: ] - PubMed
    1. Maiorca R, Cantaluppi A, Cancarini GC, Scalamogna A, Strada A, Graziani G, et al. 'Y' connector system for prevention of peritonitis in CAPD: a controlled study. Proceedings of the European Dialysis & Transplant Association 1983;20:223‐9. [MEDLINE: ] - PubMed
Naylor 1997 {published data only}
    1. Naylor M, Roe B. A study of the efficacy of dressings in preventing infections of continuous ambulatory peritoneal dialysis catheter exit sites. Journal of Clinical Nursing 1997;6(1):17‐24. [MEDLINE: ] - PubMed
Oh 2000 {published data only}
    1. Klaus G, Baum H, Wuhl E, Schaefer F, European Pediatric Peritoneal Dialysis Study Group (EPPS). Efficacy of Mupirocin prophylaxis in reducing the incidence of peritoneal dialysis (PD)‐related Staphylococcus aureus infections in children on chronic PD: results of a double blind, placebo‐controlled trial [abstract]. Peritoneal Dialysis International 2002;22(1):149. [CENTRAL: CN‐00401508]
    1. Oh J, Baum H, Klaus G, Schaefer F. Nasal carriage of staphylococcus aureus in families of children on peritoneal dialysis. European Pediatric Peritoneal Dialysis Study Group (EPPS). Advances in Peritoneal Dialysis 2000;16:324‐7. [MEDLINE: ] - PubMed
Plum 1997a {published data only}
    1. Artic S, Busch T, Sahin K, Grabensee B, Plum J. Oral versus intraperitoneal application of clindamycin in tunnel infections: a prospective, randomized study in CAPD patients [abstract]. Journal of the American Society of Nephrology 1997;8(Program & Abstracts):260A‐1A. - PubMed
    1. Plum J, Artik S, Busch T, Sahin K, Grabensee B. Oral versus intraperitoneal application of clindamycin in tunnel infections: a prospective, randomized study in CAPD patients. Peritoneal Dialysis International 1997;17(5):486‐92. [MEDLINE: ] - PubMed
Rodriguez‐Perez 1989 {published data only}
    1. Rodriguez‐Perez JC, Vega N, Plaza C, Fernandez A, Hortal L, Palop L. Prospective randomized trial with the use of antibiotic bonding to peritoneal catheters. A method to reduce tunnel and exit site infection in CAPD patients [abstract]. Kidney International 1989;36(1):154.
Thomae 1982 {published data only}
    1. Thomae U, Boos W, Adam D. Transperitoneal resorption of ampicillin, cefuroxim and gentamicin in continuous ambulatory peritoneal dialysis [Transperitoneale resorption von ampicillin, cefuroxim and gentamicin unter kontinuierlicher ambulanter peritonealdialyse]. Medizinische Welt 1982;33(5):182‐4. [MEDLINE: ] - PubMed
Trooskin 1990 {published data only}
    1. Trooskin SZ, Harvey RA, Lennard TW, Greco RS. Failure of demonstrated clinical efficacy of antibiotic‐bonded continuous ambulatory peritoneal dialysis (CAPD) catheters. Peritoneal Dialysis International 1990;10(1):57‐9. [MEDLINE: ] - PubMed

References to ongoing studies

NCT02547103 {published data only}
    1. Ruengorn C. Efficacy and safety of local application of chlorhexidine gluconate versus mupirocin ointment in the prevention of peritoneal dialysis‐related infection: a pilot study, double‐ blind, stratified randomized controlled trial. www.clinicaltrials.gov/ct2/show/NCT02547103 (accessed 28 December 2016).

Additional references

Annigeri 2001
    1. Annigeri R, Conly J, Vas S, Dedier H, Prakashan K P, Bargman JM, et al. Emergence of mupirocin‐resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit‐site infection. Peritoneal Dialysis International 2001;21(6):554‐9. [MEDLINE: ] - PubMed
Campbell 2015
    1. Campbell DJ, Johnson DW, Mudge DW, Gallagher MP, Craig JC. Prevention of peritoneal dialysis‐related infections. Nephrology Dialysis Transplantation 2015;30(9):1461‐72. [MEDLINE: ] - PubMed
Canadian CAPD Clinical Trials Group 1989
    1. Anonymous. Peritonitis in continuous ambulatory peritoneal dialysis (CAPD): a multi‐centre randomized clinical trial comparing the Y connector disinfectant system to standard systems. Canadian CAPD Clinical Trials Group. Peritoneal Dialysis International 1989;9(3):159‐63. [MEDLINE: ] - PubMed
Cho 2014
    1. Cho Y, Johnson DW. Peritoneal dialysis‐related peritonitis: towards improving evidence, practices, and outcomes. American Journal of Kidney Diseases 2014;64(2):278‐89. [MEDLINE: ] - PubMed
Choi 2004
    1. Choi P, Nemati E, Banerjee A, Preston E, Levy J, Brown E. Peritoneal dialysis catheter removal for acute peritonitis: a retrospective analysis of factors associated with catheter removal and prolonged postoperative hospitalization. American Journal of Kidney Diseases 2004;43(1):103‐11. [MEDLINE: ] - PubMed
Chow 2005
    1. Chow KM, Szeto CC, Leung CB, Kwan BC, Law MC, Li PK. A risk analysis of continuous ambulatory peritoneal dialysis‐related peritonitis. Peritoneal Dialysis International 2005;25(4):374‐9. [MEDLINE: ] - PubMed
Churchill 1997
    1. Churchill DN, Thorpe KE, Vonesh EF, Keshaviah PR. Lower probability of patient survival with continuous peritoneal dialysis in the United States compared with Canada. Canada‐USA (CANUSA) Peritoneal Dialysis Study Group. Journal of the American Society of Nephrology 1997;8(6):965‐71. [MEDLINE: ] - PubMed
Collier 2008
    1. Collier M, Evans D, Farrington M, Gibbs E, Gould K, Jenkinson H, et al. Surgical site infection: prevention and treatment. Clinical guideline [CG74], 2008. www.nice.org.uk/guidance/cg74 (accessed 28 December 2016):1‐31.
Daly 2001
    1. Daly CD, Campbell MK, MacLeod AM, Cody DJ, Vale LD, Grant AM, et al. Do the Y‐set and double‐bag systems reduce the incidence of CAPD peritonitis? A systematic review of randomized controlled trials. Nephrology Dialysis Transplantation 2001;16(2):341‐7. [MEDLINE: ] - PubMed
Dasgupta 1994
    1. Dasgupta MK. Silver peritoneal catheters reduce bacterial colonization. Advances in Peritoneal Dialysis 1994;10:195‐8. [MEDLINE: ] - PubMed
Davies 1989
    1. Davies SJ, Ogg CS, Cameron JS, Poston S, Noble WC. Staphylococcus aureus nasal carriage, exit‐site infection and catheter loss in patients treated with continuous ambulatory peritoneal dialysis (CAPD). Peritoneal Dialysis International 1989;9(1):61‐4. [MEDLINE: ] - PubMed
Digenis 1990
    1. Digenis GE, Abraham G, Savin E, Blake P, Dombros N, Sombolos K, et al. Peritonitis‐related deaths in continuous ambulatory peritoneal dialysis (CAPD) patients. Peritoneal Dialysis International 1990;10(1):45‐7. [MEDLINE: ] - PubMed
Farias 1994
    1. Farias MG, Soucie JM, McClellan W, Mitch WE. Race and the risk of peritonitis: an analysis of factors associated with the initial episode. Kidney International 1994;46(5):1392‐6. [MEDLINE: ] - PubMed
Figueiredo 2010
    1. Figueiredo A, Goh BL, Jenkins S, Johnson DW, Mactier R, Ramalakshmi S, et al. Clinical practice guidelines for peritoneal access. Peritoneal Dialysis International. 2010; Vol. 30, issue 4:424‐9. [MEDLINE: ] - PubMed
Fine 1994
    1. Fine A, Cox D, Bouw M. Higher incidence of peritonitis in native Canadians on continuous ambulatory peritoneal dialysis. Peritoneal Dialysis International 1994;14(3):227‐30. [MEDLINE: ] - PubMed
Fried 1996
    1. Fried LF, Bernardini J, Johnston JR, Piraino B. Peritonitis influences mortality in peritoneal dialysis patients. Journal of the American Society of Nephrology 1996;7(10):2176‐82. [MEDLINE: ] - PubMed
Fung 1996
    1. Fung LC, Khoury AE, Vas SI, Smith C, Oreopoulos DG, Mittelman MW. Biocompatibility of silver‐coated peritoneal dialysis catheter in a porcine model. Peritoneal Dialysis International 1996;16(4):398‐405. [MEDLINE: ] - PubMed
Ghali 2011
    1. Ghali JR, Bannister KM, Brown FG, Rosman JB, Wiggins KJ, Johnson DW, et al. Microbiology and outcomes of peritonitis in Australian peritoneal dialysis patients. Peritoneal Dialysis International 2011;31(6):651‐62. [MEDLINE: ] - PubMed
Golper 1996
    1. Golper TA, Brier ME, Bunke M, Schreiber MJ, Bartlett DK, Hamilton RW, et al. Risk factors for peritonitis in long‐term peritoneal dialysis: the Network 9 peritonitis and catheter survival studies. Academic Subcommittee of the Steering Committee of the Network 9 Peritonitis and Catheter Survival Studies. American Journal of Kidney Diseases 1996;28(3):428‐36. [MEDLINE: ] - PubMed
Guyatt 2008
    1. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck‐Ytter Y, Alonso‐Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924‐6. [MEDLINE: ] - PMC - PubMed
Heaf 2004
    1. Heaf J. Underutilization of peritoneal dialysis. JAMA 2004;291(6):740‐2. [MEDLINE: ] - PubMed
HICPAC 1995
    1. Hospital Infection Control Practices Advisory Committee (HICPAC). Recommendations for preventing the spread of vancomycin resistance.[Erratum appears in Infect Control Hosp Epidemiol 1995 Sep;16(9):498]. Infection Control & Hospital Epidemiology 1995;16(2):105‐13. [MEDLINE: ] - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. [MEDLINE: ] - PMC - PubMed
Higgins 2011
    1. Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Holley 1993
    1. Holley JL, Bernardini J, Piraino B. A comparison of peritoneal dialysis‐related infections in black and white patients. Peritoneal Dialysis International 1993;13(1):45‐9. [MEDLINE: ] - PubMed
Jaar 2009
    1. Jaar BG, Plantinga LC, Crews DC, Fink NE, Hebah N, Coresh J, et al. Timing, causes, predictors and prognosis of switching from peritoneal dialysis to hemodialysis: a prospective study. BMC Nephrology 2009;10:3. [MEDLINE: ] - PMC - PubMed
Jain 2012
    1. Jain AK, Blake P, Cordy P, Garg AX. Global trends in rates of peritoneal dialysis. Journal of the American Society of Nephrology 2012;23(3):533‐44. [MEDLINE: ] - PMC - PubMed
Johnson 2014
    1. Johnson DW, Badve SV, Pascoe EM, Beller E, Cass A, Clark C, et al. Antibacterial honey for the prevention of peritoneal‐dialysis‐related infections (HONEYPOT): a randomised trial. Lancet Infectious Diseases 2014;14(1):23‐30. [MEDLINE: ] - PubMed
Keane 2000
    1. Keane WF, Bailie GR, Boeschoten E, Gokal R, Golper TA, Holmes CJ, et al. Adult peritoneal dialysis‐related peritonitis treatment recommendations: 2000 update.[Erratum appears in Perit Dial Int 2000 Nov‐Dec;20(6):828‐9]. Peritoneal Dialysis International 2000;20(4):396‐411. [MEDLINE: ] - PubMed
Lim 2005
    1. Lim WH, Johnson DW, McDonald SP. Higher rate and earlier peritonitis in Aboriginal patients compared to non‐Aboriginal patients with end‐stage renal failure maintained on peritoneal dialysis in Australia: analysis of ANZDATA. Nephrology 2005;10(2):192‐7. [MEDLINE: ] - PubMed
Lloyd 2013
    1. Lloyd A, Tangri N, Shafer LA, Rigatto C, Perl J, Komenda P, et al. The risk of peritonitis after an exit site infection: a time‐matched, case‐control study. Nephrology Dialysis Transplantation 2013;28(7):1915‐21. [MEDLINE: ] - PubMed
McDonald 2004
    1. McDonald SP, Collins JF, Rumpsfeld M, Johnson DW. Obesity is a risk factor for peritonitis in the Australian and New Zealand peritoneal dialysis patient populations. Peritoneal Dialysis International 2004;24(4):340‐6. [MEDLINE: ] - PubMed
Moher 1998
    1. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet 1998; Vol. 352, issue 9128:609‐13. [MEDLINE: ] - PubMed
Morton 2011
    1. Morton RL, Tong A, Webster AC, Snelling P, Howard K. Characteristics of dialysis important to patients and family caregivers: a mixed methods approach. Nephrology Dialysis Transplantation 2011;26(12):4038‐46. [MEDLINE: ] - PubMed
Nessim 2009
    1. Nessim SJ, Bargman JM, Austin PC, Nisenbaum R, Jassal SV. Predictors of peritonitis in patients on peritoneal dialysis: results of a large, prospective Canadian database. Clinical Journal of The American Society of Nephrology: CJASN 2009;4(7):1195‐200. [MEDLINE: ] - PMC - PubMed
Nolph 1987
    1. Nolph KD, Cutler SJ, Steinberg SM, Novak JW, Hirschman GH. Factors associated with morbidity and mortality among patients on CAPD. ASAIO Transactions 1987;33(2):57‐65. [MEDLINE: ] - PubMed
Oxton 1994
    1. Oxton LL, Zimmerman SW, Roecker EB, Wakeen M. Risk factors for peritoneal dialysis‐related infections. Peritoneal Dialysis International 1994;14(2):137‐44. [MEDLINE: ] - PubMed
Perez‐Fontan 1993
    1. Perez‐Fontan M, Garcia‐Falcon T, Rosales M, Rodriguez‐Carmona A, Adeva M, Rodriguez‐Lozano I, et al. Treatment of Staphylococcus aureus nasal carriers in continuous ambulatory peritoneal dialysis with mupirocin: long‐term results. American Journal of Kidney Diseases 1993;22(5):708‐12. [MEDLINE: ] - PubMed
Piraino 1989
    1. Piraino B, Bernardini J, Sorkin M. Catheter infections as a factor in the transfer of continuous ambulatory peritoneal dialysis patients to hemodialysis. American Journal of Kidney Diseases 1989;13(5):365‐9. [MEDLINE: ] - PubMed
Piraino 1990
    1. Piraino B. A review of Staphylococcus aureus exit‐site and tunnel infections in peritoneal dialysis patients. American Journal of Kidney Diseases 1990;16(2):89‐95. [MEDLINE: ] - PubMed
Piraino 1998
    1. Piraino B. Peritonitis as a complication of peritoneal dialysis. Journal of the American Society of Nephrology 1998;9(10):1956‐64. [MEDLINE: ] - PubMed
Piraino 2000
    1. Piraino B. Staphylococcus aureus infections in dialysis patients: focus on prevention. ASAIO Journal 2000;46(6):S13‐7. [MEDLINE: ] - PubMed
Piraino 2002
    1. Piraino B. ADEMEX: how should it change our practice? Adequacy of peritoneal dialysis in Mexico. Peritoneal Dialysis International 2002;22(5):552‐4. [MEDLINE: ] - PubMed
Piraino 2011
    1. Piraino B, Bernardini J, Brown E, Figueiredo A, Johnson DW, Lye WC, et al. ISPD position statement on reducing the risks of peritoneal dialysis‐related infections. Peritoneal Dialysis International 2011;31(6):614‐30. [MEDLINE: ] - PubMed
Salusky 1997
    1. Salusky IB, Holloway M. Selection of peritoneal dialysis for pediatric patients. Peritoneal Dialysis International 1997;17 Suppl 3:S35‐7. [MEDLINE: ] - PubMed
Schaefer 2003
    1. Schaefer F. Management of peritonitis in children receiving chronic peritoneal dialysis. Paediatric Drugs 2003;5(5):315‐25. [MEDLINE: ] - PubMed
Schulz 1995
    1. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408‐12. [MEDLINE: ] - PubMed
Schünemann 2011a
    1. Schünemann HJ, Oxman AD, Higgins JP, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Schünemann 2011b
    1. Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Sutherland 1985
    1. Sutherland R, Boon RJ, Griffin KE, Masters PJ, Slocombe B, White AR. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. Antimicrobial Agents & Chemotherapy 1985;27(4):495‐8. [MEDLINE: ] - PMC - PubMed
Thodis 2000
    1. Thodis E, Passadakis P, Panagoutsos S, Bacharaki D, Euthimiadou A, Vargemezis V. The effectiveness of mupirocin preventing Staphylococcus aureus in catheter‐related infections in peritoneal dialysis. Advances in Peritoneal Dialysis 2000;16:257‐61. [MEDLINE: ] - PubMed
Troidle 1998
    1. Troidle L, Gorban‐Brennan N, Kliger A, Finkelstein F. Differing outcomes of gram‐positive and gram‐negative peritonitis. American Journal of Kidney Diseases 1998;32(4):623‐8. [9774124] - PubMed
Troidle 2003
    1. Troidle L, Watnick S, Wuerth DB, Gorban‐Brennan N, Kliger AS, Finkelstein FO. Depression and its association with peritonitis in long‐term peritoneal dialysis patients. American Journal of Kidney Diseases 2003;42(2):350‐4. [MEDLINE: ] - PubMed
Van Biesen 2014
    1. Biesen W, Jorres A. Medihoney: let nature do the work?. Lancet Infectious Diseases 2014;14(1):2‐3. [MEDLINE: ] - PubMed
van Diepen 2012
    1. Diepen AT, Tomlinson GA, Jassal SV. The association between exit site infection and subsequent peritonitis among peritoneal dialysis patients. Clinical Journal of The American Society of Nephrology: CJASN 2012;7(8):1266‐71. [MEDLINE: ] - PMC - PubMed
Walker 2014
    1. Walker A, Bannister K, George C, Mudge D, Yehia M, Lonergan M, et al. KHA‐CARI Guideline: peritonitis treatment and prophylaxis. Nephrology 2014; Vol. 19, issue 2:69‐71. [MEDLINE: ] - PubMed
Ward 1986
    1. Ward RA, Chang BS. Systems and devices used for peritoneal dialysis. Medical Instrumentation 1986;20(2):85‐92. [MEDLINE: ] - PubMed
Woodrow 1997
    1. Woodrow G, Turney JH, Brownjohn AM. Technique failure in peritoneal dialysis and its impact on patient survival. Peritoneal Dialysis International 1997;17(4):360‐4. [MEDLINE: ] - PubMed
Woodrow 2010
    1. Woodrow G, Davies S. Peritoneal dialysis in CKD. 2010. www.renal.org/guidelines/modules/peritoneal‐dialysis‐in‐ckd#sthash.gkEx1... (accessed 28 December 2016).

References to other published versions of this review

Strippoli 2003
    1. Strippoli GF, Tong A, Johnson D, Schena FP, Craig JC. Anti‐infective (antiseptics and antibiotics) agents for preventing peritonitis in peritoneal dialysis patients. Cochrane Database of Systematic Reviews 2003, Issue 4. [DOI: 10.1002/14651858.CD004679] - DOI - PubMed
Strippoli 2004a
    1. Strippoli GF, Tong A, Johnson DW, Schena FP, Craig JC. Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858.CD004679.pub2] - DOI - PubMed
Strippoli 2004b
    1. Strippoli GF, Tong A, Johnson D, Schena FP, Craig JC. Antimicrobial agents to prevent peritonitis in peritoneal dialysis: A systematic review of randomized controlled trials. American Journal of Kidney Diseases 2004;44(4):591‐603. [MEDLINE: ] - PubMed

MeSH terms

LinkOut - more resources

-